HBV Mutation Detail Information

> M204I Search Result

Mutation Information

Mutation Site	M204I
Mutation Type	Amino acid level
Gene/Protein/Region Type	RT
Relevant Drug	lamivudine (LAM);emtricitabine (FTC);telbivudine (LDT)
Country	Zambia and South Africa

Literature Information

PubMed PMID	23892239
Disease	HBV-HIV coinfection
Published Year	2013
Journal	Journal of acquired immune deficiency syndromes (1999)
Title	HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes.
Author	Hamers RL,Zaaijer HL,Wallis CL,Siwale M,Ive P,Botes ME,Sigaloff KC,Hoepelman AI,Stevens WS,Rinke de Wit TF,PharmAccess African Studies to Evaluate Resistance (PASER).
Evidence	HBV pol sequencing demonstrated M204I (n = 3) and N236T (n = 1) resistance-associated mutations in 4 of 8 (50%) lamivudine-treated participants and none in tenofovir-treated participants.

Contents
Description

Mutation Information Note

Gene/Protein/Region Type: Virus Gene (e.g. LMP-1) or Virus Protein (e.g. Rep 68) or Virus Region (e.g. S, X)

Literature Information Note

Evidence: sentence contains this mutation information in the citation